Human Immunology News Volume 11.00 | Jan 3 2023

    By
    Laurisa Dohm
    -
    0
    60








    2023-01-03 | HIN 11.00


    Human Immunology News by STEMCELL Technologies
    Vol. 11.00 – 3 January, 2023
    TOP STORY

    Determinants of Resistance to Engineered T Cell Therapies Targeting CD19 in Large B Cell Lymphomas

    A method for simultaneous profiling of circulating tumor DNA, cell-free CAR19 retroviral fragments, and cell-free T cell receptor rearrangements enabled integration of tumor and both engineered and non-engineered T cell effector-mediated factors for assessing treatment failure and predicting outcomes.
    [Cancer Cell]

    AbstractGraphical Abstract
    ON1096CS-Wallchart Innate Lymphoid -728 x 90
    PUBLICATIONSRanked by the impact factor of the journal

    CD8+ T Cell Activation in Cancer Comprises an Initial Activation Phase in Lymph Nodes followed by Effector Differentiation within the Tumor

    By studying human tumor-draining lymph nodes (TDLNs), researchers found that activated CD8+ T cells in TDLNs shared functional, transcriptional, and epigenetic traits with TCF1+ stem-like cells in the tumor.
    [Immunity]

    AbstractGraphical Abstract

    The Ectonucleotidase CD39 Identifies Tumor-Reactive CD8+ T Cells Predictive of Immune Checkpoint Blockade Efficacy in Human Lung Cancer

    CD39 expression enriched for CD8+ T cells with features of exhaustion, tumor reactivity, and clonal expansion. Flow cytometry of 440 lung cancer biospecimens revealed weak association between CD39+ CD8+ T cells and tumoral features,
    [Immunity]

    Abstract

    CD8+ T Cell-Intrinsic Il-6 Signaling Promotes Resistance to Anti-PD-L1 Immunotherapy

    The authors identified interleukin 6 (IL-6) as a correlate of poor response to atezolizumab (anti-PD-L1) in large clinical trials of advanced kidney, breast, and bladder cancers.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract

    Neoadjuvant Therapy with Immune Checkpoint Blockade, Antiangiogenesis, and Chemotherapy for Locally Advanced Gastric Cancer

    In this single-armed, phase II, exploratory trial, researchers evaluated the efficacy of a combination of immune checkpoint inhibitors, antiangiogenesis, and chemotherapy for neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer.
    [Nature Communications]

    Full Article

    Cytokine Conjugation to Enhance T Cell Therapy

    The authors demonstrated a simple method to increase the efficacy of adoptively transferred T cells by conjugating low-dose antitumor cytokines onto cell surfaces, which could be easily integrated into the current T cell manufacturing process.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Full Article

    Identification of a Unique Subset of Tissue-Resident Memory CD4+ T Cells in Crohn’s Disease

    Scientists found that CD103+CD4+ tissue-resident memory T cells with an inflammatory phenotype were increased in the gut of Crohn’s disease patients, but not in ulcerative colitis patients.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Full Article

    PD-1highCXCR5–CD4+ Peripheral Helper T Cells Promote CXCR3+ Plasmablasts in Human Acute Viral Infection

    Investigators used COVID-19 as a model of acute viral infections and analyzed CD4+ T cell subsets associated with plasmablast expansion and clinical outcome.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Regulatory T Cells Infiltrate the Tumor-Induced Tertiary Lymphoïd Structures and Are Associated with Poor Clinical Outcome in NSCLC

    Scientists observed that Tregs showed a similar immune profile in tertiary lymphoid structures (TLS) and non-TLS areas. Autologous tumor-infiltrating Tregs inhibited the proliferation and cytokine secretion of CD4+ conventional T cells.
    [Communications Biology]

    Full Article
    ON1094CS-Eric Song webinar-728x90
    REVIEWS

    Tumor-Infiltrating Lymphocytes: From Prognosis to Treatment Selection

    New insights on novel tumor-infiltrating lymphocytes (TIL) subsets are discussed, giving a broader view on the prognostic effect of TILs in cancer.
    [British Journal Of Cancer]

    Full Article

    Non-Coding RNAs in Immunoregulation and Autoimmunity: Technological Advances and Critical Limitations

    The authors provide an overview of non-coding RNAs and review technological advances that enable their study and hold substantial promise for the future.
    [Journal Of Autoimmunity]

    Full Article
    INDUSTRY AND POLICY NEWS

    Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

    Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis and lupus.
    [Gilead Sciences Inc.]

    Full Article
    FEATURED EVENT

    Skin-Immune Crosstalk

    February 13 – 16, 2023
    Breckenridge, Colorado, United States

    > See All Events

    JOB OPPORTUNITIES

    Senior Scientist – Vaccine Immunology

    Pfizer – Pearl River, New York, United States

    Clinical Trialist – Rheumatology

    Oklahoma Medical Research Foundation – Oklahoma City, United States

    Faculty Position – Immunology, Microenvironment, and Metastasis Program

    The Wistar Institute – Philadelphia, Pennsylvania, United States

    Faculty Positions – Translational Biomedical Research

    Rutgers Biomedical and Health Sciences – Newark, New Jersey, United States

    Faculty Positions – Life Sciences

    Westlake University – Hangzhou, China

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter